UK markets close in 7 hours 10 minutes
  • FTSE 100

    7,281.71
    +72.90 (+1.01%)
     
  • FTSE 250

    19,392.11
    +268.40 (+1.40%)
     
  • AIM

    906.54
    +10.27 (+1.15%)
     
  • GBP/EUR

    1.1635
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.2313
    +0.0044 (+0.35%)
     
  • BTC-GBP

    17,367.47
    -105.10 (-0.60%)
     
  • CMC Crypto 200

    466.59
    +12.69 (+2.80%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.28 (+2.68%)
     
  • CRUDE OIL

    107.80
    +0.18 (+0.17%)
     
  • GOLD FUTURES

    1,837.50
    +7.20 (+0.39%)
     
  • NIKKEI 225

    26,871.27
    +379.30 (+1.43%)
     
  • HANG SENG

    22,201.08
    +482.02 (+2.22%)
     
  • DAX

    13,366.83
    +248.70 (+1.90%)
     
  • CAC 40

    6,155.58
    +82.23 (+1.35%)
     

What Kind Of Investors Own Most Of Altimmune, Inc. (NASDAQ:ALT)?

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls Altimmune, Inc. (NASDAQ:ALT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

Altimmune is a smaller company with a market capitalization of US$261m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Altimmune.

Check out our latest analysis for Altimmune

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Altimmune?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Altimmune. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Altimmune's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. It looks like hedge funds own 12% of Altimmune shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Looking at our data, we can see that the largest shareholder is State Street Global Advisors, Inc. with 10% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 6.9% of common stock, and Avidity Partners Management, L.P. holds about 6.4% of the company stock. In addition, we found that Vipin Garg, the CEO has 0.7% of the shares allocated to their name.

We also observed that the top 10 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Altimmune

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Altimmune, Inc.. In their own names, insiders own US$2.8m worth of stock in the US$261m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, who are usually individual investors, hold a 17% stake in Altimmune. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

We can see that Private Companies own 4.4%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Altimmune better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 5 warning signs with Altimmune (at least 1 which is concerning) , and understanding them should be part of your investment process.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting